Tower Research Capital (TRC)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-280
| Closed | -$4.14K | – | 6203 |
|
|
2024
Q1 | $4.14K | Sell |
280
-986
| -78% | -$13.9K | ﹤0.01% | 4730 |
|
|
2023
Q4 | $17K | Buy |
1,266
+102
| +9% | +$1.29K | ﹤0.01% | 3757 |
|
|
2023
Q3 | $14.4K | Sell |
1,164
-9,403
| -89% | -$114K | ﹤0.01% | 3690 |
|
|
2023
Q2 | $130K | Buy |
10,567
+9,332
| +756% | +$117K | ﹤0.01% | 1871 |
|
|
2023
Q1 | $15K | Sell |
1,235
-2,007
| -62% | -$23.6K | ﹤0.01% | 3850 |
|
|
2022
Q4 | $37K | Buy |
3,242
+3,057
| +1,652% | +$25.2K | ﹤0.01% | 2575 |
|
|
2022
Q3 | $1K | Buy |
185
+125
| +208% | +$577 | ﹤0.01% | 5996 |
|
|
2022
Q2 | $0 | Sell |
60
-133
| -69% | -$750 | ﹤0.01% | 7097 |
|
|
2022
Q1 | $1K | Sell |
193
-435
| -69% | -$2.44K | ﹤0.01% | 6025 |
|
|
2021
Q4 | $2K | Buy |
628
+561
| +837% | +$2.44K | ﹤0.01% | 5767 |
|
|
2021
Q3 | $0 | Buy |
+67
| New | +$349 | ﹤0.01% | 6673 |
|
|
2021
Q2 | – | Sell |
-2,579
| Closed | -$16K | – | 6346 |
|
|
2021
Q1 | $16K | Buy |
2,579
+631
| +32% | +$4.51K | ﹤0.01% | 4087 |
|
|
2020
Q4 | $13K | Buy |
1,948
+1,449
| +290% | +$7.15K | ﹤0.01% | 4187 |
|
|
2020
Q3 | $2K | Buy |
+499
| New | +$1.83K | ﹤0.01% | 4665 |
|
|
2020
Q2 | – | Sell |
-773
| Closed | -$2K | – | 5197 |
|
|
2020
Q1 | $2K | Sell |
773
-1,760
| -69% | -$5.15K | ﹤0.01% | 2708 |
|
|
2019
Q4 | $8K | Sell |
2,533
-309
| -11% | -$1.24K | ﹤0.01% | 2488 |
|
|
2019
Q3 | $13K | Sell |
2,842
-1,348
| -32% | -$6.74K | ﹤0.01% | 2802 |
|
|
2019
Q2 | $20K | Buy |
4,190
+3,119
| +291% | +$14.8K | ﹤0.01% | 2205 |
|
|
2019
Q1 | $6K | Sell |
1,071
-23,158
| -96% | -$106K | ﹤0.01% | 3028 |
|
|
2018
Q4 | $73K | Buy |
24,229
+3,857
| +19% | +$13.4K | 0.01% | 1107 |
|
|
2018
Q3 | $86K | Buy |
20,372
+11,202
| +122% | +$47.2K | 0.01% | 1446 |
|
|
2018
Q2 | $36K | Buy |
9,170
+6,917
| +307% | +$45.9K | ﹤0.01% | 2068 |
|
|
2018
Q1 | $14K | Buy |
+2,253
| New | +$18.6K | ﹤0.01% | 2348 |
|
|
2017
Q4 | – | Sell |
-4,389
| Closed | -$50K | – | 4461 |
|
|
2017
Q3 | $50K | Buy |
4,389
+1,155
| +36% | +$12.1K | ﹤0.01% | 1983 |
|
|
2017
Q2 | $32K | Buy |
+3,234
| New | +$66.1K | ﹤0.01% | 979 |
|
|
2017
Q1 | – | Sell |
-1,358
| Closed | -$44K | – | 4505 |
|
|
2016
Q4 | $44K | Buy |
+1,358
| New | +$57.9K | ﹤0.01% | 1523 |
|
|
2016
Q2 | – | Sell |
-127
| Closed | -$8K | – | 5391 |
|
|
2016
Q1 | $8K | Buy |
127
+51
| +67% | +$2.66K | ﹤0.01% | 2297 |
|
|
2015
Q4 | $5K | Sell |
76
-2,407
| -97% | -$169K | ﹤0.01% | 3094 |
|
|
2015
Q3 | $166K | Buy |
2,483
+1,346
| +118% | +$110K | 0.02% | 336 |
|
|
2015
Q2 | $111K | Buy |
1,137
+1,124
| +8,646% | +$107K | 0.01% | 721 |
|
|
2015
Q1 | $1K | Sell |
13
-211
| -94% | -$18K | ﹤0.01% | 4256 |
|
|
2014
Q4 | $20K | Buy |
+224
| New | +$16.3K | ﹤0.01% | 1614 |
|
|
2014
Q2 | – | Sell |
-236
| Closed | -$9K | – | 5031 |
|
|
2014
Q1 | $9K | Buy |
236
+166
| +237% | +$7.1K | ﹤0.01% | 2756 |
|
|
2013
Q4 | $3K | Sell |
70
-682
| -91% | -$19.8K | ﹤0.01% | 3914 |
|
|
2013
Q3 | $22K | Buy |
752
+349
| +87% | +$12.2K | ﹤0.01% | 2623 |
|
|
2013
Q2 | $21K | Buy |
+403
| New | +$17.7K | ﹤0.01% | 1678 |
|
Other funds holding MACK
RA
JC
Tower Research Capital (TRC)'s MACK Position: Q2 2024 in Review
Tower Research Capital (TRC) sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 280 shares — an estimated $4.14K sold.
Tower Research Capital (TRC) first reported a position in MACK in Q2 2013 and held it in 36 quarters. The position peaked at $166K in Q3 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Tower Research Capital (TRC) reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 280 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $4.14K.
- Tower Research Capital (TRC) first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 36 quarters.
- Tower Research Capital (TRC)'s Merrimack Pharmaceuticals, Inc. position peaked at $166K in Q3 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.